Apnimed to Participate in the William Blair Virtual Conference: Transitioning Biotech Breakthroughs to Commercial Success
July 12, 2023 08:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep...
Apnimed to Participate in the 2023 BIO International Convention
May 23, 2023 07:00 ET
|
Apnimed, Inc.
CAMBRIDGE, Mass., May 23, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea...
Apnimed Presented Positive Phase 2b Results on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea, for the First Time at ATS 2023
May 21, 2023 10:00 ET
|
Apnimed, Inc.
-- New MARIPOSA Study Data Showed AD109 Statistically Significantly Improved Both Objective and Subjective Outcomes in OSA Patients -- MARIPOSA Results Support Advancing AD109 to Phase 3 CAMBRIDGE,...